Introduction {#Sec1}
============

The pandemic of coronavirus disease (COVID-19) represents a multi-faceted challenge for health systems across the globe, including on issues related to diagnosis. Respiratory manifestations are the predominant presentation of COVID-19 among symptomatic patients; additionally, it is relevant to emphasize that multiple organ involvement, including the gastrointestinal tract, central nervous system, cardiovascular system, liver, bone marrow, and kidney, has been reported in patients infected with SARS-CoV-2 \[[@CR1], [@CR2]\]. As to viral tropism, the lungs are not the only COVID-19 target, but the kidneys also may be involved in a significant percentage of infected patients, particularly in those severely affected \[[@CR3]\]. When compared with adults, COVID-19 is less frequent in the pediatric population, and typically presents respiratory syndrome \[[@CR1], [@CR4]\]; however, the virus can produce unusual manifestations in children, e.g., Kawasaki's disease and gastrointestinal syndrome, and epidemiological studies have shown that children are at lower risk of critical illness \[[@CR1], [@CR2], [@CR5]\].

Information about COVID-19 in children with nephropathies is lacking; a report from Spain described 16 patients with chronic kidney diseases presenting mild respiratory symptoms and few radiological manifestations. Of these, glomerular filtration worsened in three, and two patients with steroid-dependent nephrotic syndrome had relapse \[[@CR6]\].

Isolated nephrological manifestations in COVID-19 have also been reported: hematuria in a pediatric case \[[@CR7]\] and hematuria and albuminuria in critical patients, suggesting an association of COVID-19 with nephritis glomerular changes \[[@CR8]\]. Nephritis-like histology was also described in postmortem samples from patients with COVID-19 \[[@CR9]\].

Herein we describe a case of SARS-CoV-2 infection presenting with a complete picture of onset of nephrotic syndrome along with respiratory symptoms in a pediatric patient.

Case report {#Sec2}
===========

A 15-year-old boy was admitted in April 2020 with fever, generalized edema, myalgias, and oliguria. In a matter of hours, he developed progressive dyspnea, was diagnosed with nephrotic syndrome (anasarca, hypoalbuminemia, proteinuria, and hyperlipidemia), and tested positive for SARS-CoV-2 infection.

Antecedents: urinary tract infection in infancy, vomiting, and diarrhea 3 months prior with recurrence one month later; urine tests were normal during both evaluations.

At admission: weight: 55 kg, height: 167 cm, blood pressure: 140/70 mmHg, moderate intercostal retraction, mild ascites, pain in left knee. Urine test: protein +++, no hematuria, Hb: 12.8 g/dl, HTC: 33.6%, total protein: 3.9 mg%, albumin: 1.5 mg%, leukocytes: 5600/mm^3^, platelets: 224.000/mm^3^, Cl^−^: 102, K^+^: 5, Na^+^: 135, serum creatinine: 0.55 mg%, alkaline phosphatase: 85, T calcium: 7 mg%, Mg^+^: 2 mg%, phosphorus: 2.7 mg%, triglycerides: 240 mg%, cholesterol: 202 mg%, glucose: 101 mg%, arterial blood gases: pH: 7.44, HCO~3~: 21 meq/L, O~2~ Sat: 95%.

(*rRT-PCR*) for SARS-CoV-2 infection: positive. D Dimer initial: 32.074 ng/mL (ELFA) (reference value (RV): \< 500) and four weeks later: 1385 ng/dL, IL-6: 17.1 pg/mL (EQLM) (RV: \< 7), LDH: 743 U/L (RV: 120--300), CPK: 583 U/L (RV: 0--270), C3: 53 mg/dL (RV: 90--180), C4: 4 mg/dL (RV: 10--40), ANCAc: 1.5 U /mL (RV: \< 5), ANCAp: 1.6 U/mL (RV: \< 5), ANA (IF): 1320 U/mL (RV: \< 1.8), Ac anticardiolipin: − 5.6 GPLU/mL (RV: \< 10), Ac anticardiolipin IgM: 14.7 0MPLU/mL (RV: \< 7), Ac antiB2glycoprot IgG: 3.70 U/mL (RV: \< 5), Ac antiB2glycoprot IgM: 15.30 U/mL (RV: \< 5), hepatitis C and B: negative, hemoculture (3): negative, 24-h proteinuria: 4 g/24 h. Chest/lungs x-ray and CT scan: bilateral pleural effusion and reticular interstitial opacity in lungs. Treatment: chloroquine and azithromycin, daily boluses of methylprednisolone × 5. The patient's respiratory syndrome and edema improved and kidney biopsy will be undertaken when possible.

Discussion {#Sec3}
==========

Kidney injury has been described in viral respiratory infections including adenovirus, influenza A and B, and other pathogens. Kidney injury in patients severely affected with COVID-19 appears to be a frequent finding, with a wide range of manifestations, from microhematuria, isolated proteinuria, elevation of azotemia products in serum, and severe acute kidney injury \[[@CR3], [@CR7]\]. However, based on the data review by the researchers, a complete nephrotic picture has not been reported.

The pathogenesis of the kidney damage could be multi-factorial, including direct cytopathic effects of the virus, immune complex--mediated damage, and secondary systemic effects on kidney tissue, such as hypovolemia, hypoxia, and shock, due to the cytokine inflammatory response to the virus \[[@CR3]\].

It has been suggested that the multi-organ manifestations of COVID-19 are the consequence of angiotensin-converting enzyme 2, the receptor for SARS-CoV-2, which is responsible for host cell entry and subsequent viral replication in humans, and is broadly expressed in tissue of the alveolar epithelial cells, the myocardium, the endothelium, the gastrointestinal tract, bone marrow, kidneys, among other tissues \[[@CR10]\].

One of the most striking features of COVID-19 is the overwhelmingly lower risk of severe forms of disease in children when compared with older age groups \[[@CR6]\]. To date, there are few reported cases of kidney involvement in children with COVID-19 \[[@CR5]\].

In summary, the patient described in this report with no history of chronic kidney disease, admitted because of nephrotic syndrome and respiratory syndrome, and tested positive for COVID-19. As far as we know, this is the first reported case of COVID-19 with simultaneous onset of nephrotic syndrome; this could be either a coincidence or an unusual form of presentation of COVID-19. Pediatricians should be aware of this possibility when treating children, and test them for proteinuria, serum proteins, and blood lipids to diagnose the nephrotic condition of patients.
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